Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for Diuretic Refractory Ascites in Cirrhosis
NCT05013502Phase 1Completed
- Sponsor
- Stanford University
- Start
- Nov 2021
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of empagliflozin in ascites, sponsored by Stanford University. Primary endpoint: Participant retention rate at 12 weeks. Started Nov 2021; status: completed.
02
Drugs
empagliflozin
03
Conditions
ascites
Beyond the preview
Go deeper on NCT05013502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05013502.